valdecoxib withdrawn
Selected indexed studies
- Valdecoxib : the rise and fall of a COX-2 inhibitor. (Expert Opin Pharmacother, 2013) [PMID:23517091]
- Celecoxib and cardiovascular risks. (Expert Opin Drug Saf, 2005) [PMID:16255660]
- Antitumor effects of valdecoxib on hypopharyngeal squamous carcinoma cells. (Korean J Physiol Pharmacol, 2022) [PMID:36302619]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Valdecoxib : the rise and fall of a COX-2 inhibitor. (2013) pubmed
- Celecoxib and cardiovascular risks. (2005) pubmed
- Antitumor effects of valdecoxib on hypopharyngeal squamous carcinoma cells. (2022) pubmed
- Prostanoid receptor EP2 as a therapeutic target. (2014) pubmed
- Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies. (2006) pubmed
- Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. (2007) pubmed
- Cardiovascular effects of common analgesics. (2013) pubmed
- Cardiovascular issues of COX-2 inhibitors and NSAIDs. (2005) pubmed
- Progress in COX-2 inhibitors: a journey so far. (2010) pubmed
- cardioToxCSM: A Web Server for Predicting Cardiotoxicity of Small Molecules. (2022) pubmed